REFERENCE FILE
Bremelanotide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limitations
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
A SECOND LOOK
A question to carry into the reading
Before comparing two claims about bremelanotide, turn each outcome into a short definition. Write what would be recorded, how it would be measured, and what would qualify as a change. Keep a broad label separate from the rule that gives it meaning. If the definitions use different thresholds or instruments, describe those differences before placing the results side by side. Try writing a sentence that another reader could use to recognize the outcome without seeing its name. If that is impossible from the available description, the next task is to locate the measurement rule, not to select the more appealing number.
Questions to keep beside the page
- What would someone have to record to identify this outcome?
- Do the two claims use the same measurement rule and threshold?
- Which missing definition prevents me from making a clear comparison?
Sources for this file
- VYLEESINLM · Checked
- Kingsberg trialsPubMed · Checked
FROM THE REFERENCE DESK